Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,354,330
  • Shares Outstanding, K 188,990
  • Annual Sales, $ 9,300 K
  • Annual Income, $ -643,200 K
  • EBIT $ -544 M
  • EBITDA $ -538 M
  • 60-Month Beta 1.09
  • Price/Sales 457.90
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 132.07% ( +0.16%)
  • Historical Volatility 47.03%
  • IV Percentile 98%
  • IV Rank 82.44%
  • IV High 151.63% on 11/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 3,996
  • Volume Avg (30-Day) 4,475
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 159,786
  • Open Int (30-Day) 138,445

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.07
  • Number of Estimates 8
  • High Estimate -0.90
  • Low Estimate -1.27
  • Prior Year -0.96
  • Growth Rate Est. (year over year) -11.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.72 +7.00%
on 11/19/24
27.57 -15.71%
on 11/11/24
-1.92 (-7.63%)
since 10/21/24
3-Month
21.72 +7.00%
on 11/19/24
32.06 -27.51%
on 09/05/24
-2.32 (-9.08%)
since 08/21/24
52-Week
21.62 +7.49%
on 06/24/24
44.32 -47.56%
on 12/28/23
-5.07 (-17.91%)
since 11/21/23

Most Recent Stories

More News
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 23.24 (+0.87%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 23.24 (+0.87%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 23.24 (+0.87%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 23.24 (+0.87%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 23.24 (+0.87%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 23.24 (+0.87%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 23.24 (+0.87%)
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BBIO : 23.24 (+0.87%)
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO : 23.24 (+0.87%)
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 42.89 (+2.22%)
VRTX : 450.37 (-0.19%)
BBIO : 23.24 (+0.87%)
RHHBY : 35.2900 (+0.46%)
PFE : 25.13 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 24.45
2nd Resistance Point 24.04
1st Resistance Point 23.64
Last Price 23.24
1st Support Level 22.83
2nd Support Level 22.42
3rd Support Level 22.02

See More

52-Week High 44.32
Fibonacci 61.8% 35.65
Fibonacci 50% 32.97
Fibonacci 38.2% 30.29
Last Price 23.24
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar